<DOC>
	<DOCNO>NCT00000650</DOCNO>
	<brief_summary>To determine , HIV-infected patient , magnitude duration biological effect ditiocarb sodium ( sodium diethyldithiocarbamate ; DTC ) may relevant treatment HIV infection . DTC study previous clinical trial HIV-infected patient suggestion delay disease progression AIDS improvement CD4 count drug .</brief_summary>
	<brief_title>An Assessment In Vivo Biological Effects Diethyldithiocarbamate ( DTC ) HIV-Infected Patients</brief_title>
	<detailed_description>DTC study previous clinical trial HIV-infected patient suggestion delay disease progression AIDS improvement CD4 count drug . Two group patient , one group asymptomatic AIDS diagnosis , enrol study . All patient receive DTC intravenously week two week . Drugs give day 1 8 . Blood sample draw day 1 , 3 , 5 , 8 , 10 , 12 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ditiocarb</mesh_term>
	<criteria>Inclusion Criteria Patients must : Have HIV infection . Be asymptomatic ( group 1 ) AIDS ( group 2 ) . Be able understand follow instruction . Concurrent Medication : Allowed : GROUP 2 : AntiHIV therapy . Systemic prophylaxis maintenance therapy AIDSdefining opportunistic infection exclude agent consider immunomodulators immunosuppressant . Topical nystatin . Clotrimazole troche . Acyclovir . Dapsone . Trimethoprim / sulfamethoxazole ( T/S ) . Fluconazole . Ketoconazole . Aerosolized pentamidine . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : ALL PATIENTS : Known hypersensitivity disulfiram diethyldithiocarbamate ( DTC ) . Transfusion dependence . GROUP 1 PATIENTS ONLY : Oral candidiasis document morphology response antifungal therapy . Oral hairy leukoplakia . Occurrence herpes zoster single dermatomal distribution . Recurrent seborrheic dermatitis . Unintentional weight loss excess 10 pound 10 percent usual body weight within 2 year prior study . Unexplained temperature 38 degree C 5 consecutive day 10 day 30 day within 2 year expect study entry . Unexplained diarrhea define two stools/day least 14 day 120day interval . Evidence clinically significant cardiac , respiratory , hepatic , gastrointestinal , endocrine , hematologic , psychiatric , neurologic , renal , dermatologic disease demonstrate history , physical , laboratory evaluation . GROUP 2 PATIENTS ONLY : Concurrent neoplasm Kaposi 's sarcoma basal cell carcinoma skin . Diagnosis acute opportunistic infection within 3 week study entry treatment initiate opportunistic infection within 3 week study entry . Concurrent Medication : Excluded : ALL PATIENTS : Recombinant erythropoietin . GROUP 1 : Antiretroviral medication . GROUP 2 : Immunomodulators immunosuppressant . Concurrent Treatment : Excluded : Requirement blood transfusion month . Patients follow prior condition exclude : GROUP 1 PATIENTS ONLY : Oral candidiasis document morphology response antifungal therapy . Oral hairy leukoplakia . Occurrence herpes zoster single dermatomal distribution . Recurrent seborrheic dermatitis . Unintentional weight loss excess 10 pound 10 percent usual body weight within 2 year prior study . Unexplained temperature 38 degree C 5 consecutive day 10 day 30day period within 2 year expect study entry . Unexplained diarrhea define two stools/day least 14 day 120day interval . Evidence clinically significant cardiac , respiratory , hepatic , gastrointestinal , endocrine , hematologic , psychiatric , neurologic , renal , dermatologic disease demonstrate history , physical , laboratory evaluation . GROUP 2 PATIENTS ONLY : Diagnosis acute opportunistic infection within 3 week study entry treatment initiate opportunistic infection within 3 week study entry . Prior Medication : Excluded : ALL PATIENTS : Corticosteroids , cytotoxic agent , immunomodulating agent within 30 day prior study entry . Chronic Antabuse ( disulfiram ) therapy . GROUP 1 ONLY : Antiretrovial medication within 1 week prior study entry . Prior Treatment : Excluded : Transfusion within 7 day study entry . Radiation therapy within 30 day prior study entry . Unable refrain use alcohol duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Drug Evaluation</keyword>
	<keyword>Ditiocarb</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>